Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1256P - Value of detection of peripheral blood circRNA based on digital PCR in the diagnosis of lung adenocarcinoma

Date

21 Oct 2023

Session

Poster session 14

Topics

Cancer Diagnostics

Tumour Site

Presenters

Jihong Zhou

Citation

Annals of Oncology (2023) 34 (suppl_2): S711-S731. 10.1016/S0923-7534(23)01942-7

Authors

J. Zhou, W. Li, W. Sun, C. Zhou, Q. Wang

Author affiliations

  • Department Of Respiratory Medicine, The First Affiliated Hospital of Bengbu Medical College, 233004 - Bengbu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1256P

Background

Lung cancer is a cancer type with high morbidity and mortality in the word, the clinical prognosis of lung cancer patients is still poor, the main reason is the lack of effective early screening and diagnosis methods. Plasma circRNAs detected by droplet digital PCR may be ideal markers for liquid biopsy. However, droplet digital PCR detection of circRNAs in plasma for (early) diagnosis of lung adenocarcinoma has been rarely reported.

Methods

RNA sequencing analysis was performed in plasma from patients with early lung adenocarcinoma and healthy individuals. Droplet digital PCR was used to verify the differentially expressed genes. We evaluated their diagnostic efficacy and predict their biological functions of target genes.

Results

The copy numbers of circLZIC and circCEP350 in the plasma of lung adenocarcinoma patients were significantly higher than in plasma of healthy people (P<0.01), they are closely related to tumor size (P<0.05) and TNM stage (P<0.05),and the copy numbers in postoperative plasma of the same patient were significantly lower than those in preoperative plasma (P<0.05).ROC curve analysis showed that circLZIC (AUC=0.782) and circCEP350 (AUC=0.764) alone and in combination (AUC=0.863) had diagnostic value in lung adenocarcinoma, circLZIC (AUC=0.786) and circCEP350 (AUC=0.546) alone and in combination (AUC=0.803) had diagnostic value in early lung adenocarcinoma.Bioinformatics analysis revealed that circLZIC and circCEP350 had more binding sites with multiple microRNAs. Their target genes were enriched in several signaling pathways.

Conclusions

The copy numbers of circLZIC and circCEP350 were higher in plasma of lung adenocarcinoma patients than in plasma of healthy controls, significantly correlated with tumor size and TNM stage, and closely related to the occurrence and development of tumors. These circRNAs may serve as molecular markers for the diagnosis of lung adenocarcinoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.